|
|
|
  |
Pediatric Pharmacology Europe |
|
13th-14th
September 2010 |
This will be a
two-day meeting for clinical
pharmacologists, scientists and
pediatricians to discuss overcoming the
scientific challenges using tools such as
models & simulations and PK & PD studies to
optimise the development of new pediatric
medicines.
 |
|
|
|
|
|
  |
|
2nd Annual Pharmaceutical
Risk-Sharing & Value-Based Pricing & Reimbursement Model |
|
14th-15th
September 2010 |
|
There is clearly an increasing need for more
innovative pricing and reimbursement agreements
to help to balance the often conflicting
objectives of pharmaceutical and medical
technology manufacturers, payers, health plans,
health technology assessment (HTA) & physicians
and patients. The industry faces a sustained
increase in the cost of healthcare and an
ever-increase in the range of expensive drugs
and technologies available as potential
therapies. In light of this, difficult choices
need to be made by payers and HTAs about which
products receive funding from increasingly
restricted healthcare budgets, especially with
often insufficient clinical and real-life
evidence available.
|
|
|
|
|
|
|
|
|
2nd Annual Pharmaceutical
Market & Patient Access for Chronic Disease Therapies |
|
14th-15th
September 2010 |
|
Chronic diseases are taking a steadily
increasing share of national health spending in
the developed world, especially due to an ageing
population and unhealthy lifestyles. Such
conditions and treatments do not often seem as
controversial and as high on the political,
healthcare system and media‘s agenda, when
compared to the very expensive cancer or orphan
drugs, for example. Typically, drugs for chronic
diseases are priced at very reasonable levels,
yet are making a large budget impact, effecting
significant percentages of the entire
population. The total number of patients are
growing from year to year as medicines improve
in efficacy and patients live longer. Health
spending on long-term diseases, is indeed a
long-term problem for payers, who are now
looking to reprioritise budgets in a difficult
economic environment and also allocate more
resources to prevention, earlier diagnosis,
improved managed care, disease management,
reducing wastage through better patient
adherence and investing in one-off surgical
procedures involving medical devices.
|
|
|
|
|
|
|
|
|
Advancing Biologics from the lab to
the clinic |
|
16th-17th
September 2010 |
|
The development of biologics encounter the same
familiar hurdles as their small molecule
counterparts: escalating development costs,
identifying novel targets with unproven therapeutic
potential, and regulatory agencies demanding more
compelling demonstrations of the value of new
products. However, clinical development for
biologics is considered to be more challenging,
expensive, and risky than small molecule
development. Besides the standard considerations of
safety and efficacy, a clinical development program
should also consider immunogenicity, optimal dosage
levels, and the evaluation of available biomarkers
and imaging technologies to measure the effects on a
given target. These critical issues have many
biopharma companies rethinking their clinical
development strategies in order to design a program
that caters to the unique properties of biologics.
|
|
|
|
|
|
|
|
|
Pediatric Pharmacology USA |
|
20th-21st
September 2010 |
This will be a
two-day meeting for clinical
pharmacologists, scientists and
pediatricians to discuss overcoming the
scientific challenges using tools such as
models & simulations and PK & PD studies to
optimise the development of new pediatric
medicines.
|
|
|
|
|
|
  |
|
Pharmaceutical
Pricing & Reimbursement in Turkey |
|
22nd September-2010 |
Turkey is an exciting,
high-growth potential market for
pharmaceutical manufacturers. Market access
however, is a complicated task in Turkey and
requires an excellent understanding of all
stakeholders' initiatives and views.
With a real intention to change the current
situation and shape advanced processes:
governmental bodies, the pharma industry and
leading academics are strongly advocating
initiatives such as HTA establishment and
increasing transparency of reimbursement
processes. Although the mission ahead is
complicated and is raising a number of
debates, it seems like the process has
started and pricing and reimbursement models
will be clearer in the short to medium
terms.
|
|
|
|
|
|
|
|
|
Advancing Clinical
Research in Turkey, Middle East & North Africa |
|
23th-24th September-2010 |
Industry sponsored
clinical trials are increasingly conducted
in emerging regions, due to escalating
competition and high costs in the more
established territories of North America and
Western Europe. As companies search for
advantages and new opportunities, factors
such as large and eager patient populations,
competitive trial budgets, and faster
recruitment rates at fewer sites are
prompting a fundamental geographic shift in
the location of studies.
|
|
|
|
|
|
|
|
|
5th Annual Clinical
Outsourcing Partnerships In Central & Eastern Europe |
|
27th-28th September-2010 |
Central & Eastern
Europe continues to be a standout region for high
quality clinical research, with its well-trained
investigators and large patient populations. Due to
this popularity the clinical outsourcing environment
in CEE & Russia is becoming more complex and
difficult to navigate. This event will examine the
multitude of outsourcing practices being used in the
region today, as over the past 2-3 years several
powerful yet inherently different outsourcing
cultures have emerged in the region. These Preferred
Provider and Functional Service Provider models have
evolved in the region at varying levels of success
and they both bring with them a multitude of
opportunities and challenges for sponsors and
clinical solution providers alike.
|
|
|
|
|
|
|
|
|
Optimizing Early
Phase Oncology Studies to Accelerate Proof of
Concept |
|
29th-30th September-2010 |
When running early clinical trials for experimental
new drugs across a range of therapeutic areas,
demonstrating "proof of concept" is a critical
milestone of the development process. It is at this
stage where exploratory studies become confirmatory
studies and there is a basis for studying the
efficacy in a larger population. From a business
perspective, showing proof of concept is also an
essential bargaining chip when negotiating licensing
agreements.
|
|
|
|
|
|
I
back
I
top
I |
|
All rights reserved